Enhancing T Cell Function for Cancer immunotherapy With CRISPR

T cell exhaustion is the bane of any cellular immunotherapy – terminally exhausted T cells fail to persist and proliferate in vivo and are unable to clear tumours. Despite being well characterised, a solution to the problem of T cell dysfunction has remained elusive.

Evidence published in Cancer Cell in 2022 identified chromatin remodelling factor Arid1A as a key regulator of T cell dysfunction. The result of a collaboration between Stanford University, University of California San Francisco, the Innovative Genomics Institute, and the Memorial Sloan Kettering Cancer Center, the study demonstrates that CRISPR-based knockout of Arid1A reverses the exhausted state of T cells in vitro and in vivo.

What will you learn from this webinar:

• Genome-wide CRISPR screens dissect persistence, proliferation, and cytokine secretion in primary T cells
• Subunits of the canonical BAF complex and the Mediator complex are new targets for CRISPR-engineered T cell therapies
• Modulating the T cell epigenome can improve T cell responses in cancer immunotherapy

Webinar Programme:

• 15.00 Welcome and introduction by CRISPR Medicine News
• 15.05 Dr. Julia Belk Ph.D. Postdoctoral Scholar | Enhancing T Cell Function for Cancer immunotherapy With CRISPR
• 15.45 Q & A with Dr. Julia Belk
• 16.00 Close by CRISPR Medicine News

Speaker | Title:

Dr. Julia Belk Ph.D. Postdoctoral Scholar, Stanford University, USA | Enhancing T Cell Function for Cancer immunotherapy With CRISPR